Protara Therapeutics, Inc. Variable Lease, Cost
Protara Therapeutics, Inc. (TARA) reported Variable Lease, Cost of $34.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-11
- Protara Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $34.00K, a 9.68% increase year-over-year.
- Protara Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $32.00K, a 3.23% increase year-over-year.
- Protara Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $31.00K, a 14.81% increase year-over-year.
- Protara Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $31.00K, a 19.23% increase year-over-year.
- Protara Therapeutics, Inc. variable lease, cost for fiscal 2025 was $124.00K, a 25.25% increase from fiscal 2024.
- Protara Therapeutics, Inc. variable lease, cost for fiscal 2024 was $99.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.00K 10-Q · filed 2026-08-11 | $66.00K 10-Q · filed 2026-08-11 | $97.00K derived: sum of 3 quarters · filed 2026-08-11 | $128.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $32.00K 10-Q · filed 2026-05-13 | $63.00K derived: sum of 2 quarters · filed 2026-05-13 | $94.00K derived: sum of 3 quarters · filed 2026-05-13 | $125.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $62.00K derived: sum of 2 quarters · filed 2026-03-10 | $93.00K derived: sum of 3 quarters · filed 2026-08-11 | $124.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $31.00K 10-Q · filed 2025-11-10 | $62.00K derived: sum of 2 quarters · filed 2026-08-11 | $93.00K 10-Q · filed 2025-11-10 | $120.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $31.00K 10-Q · filed 2026-08-11 | $62.00K 10-Q · filed 2026-08-11 | $89.00K derived: sum of 3 quarters · filed 2026-08-11 | $115.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $31.00K 10-Q · filed 2026-05-13 | $58.00K derived: sum of 2 quarters · filed 2026-05-13 | $84.00K derived: sum of 3 quarters · filed 2026-05-13 | $110.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $53.00K derived: sum of 2 quarters · filed 2026-03-10 | $79.00K derived: sum of 3 quarters · filed 2026-03-10 | $99.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $26.00K 10-Q · filed 2025-11-10 | $52.00K derived: sum of 2 quarters · filed 2025-11-10 | $72.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $26.00K 10-Q · filed 2025-08-11 | $46.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $20.00K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |